Gadolinium-Doped Hydroxyapatite Nanorods as T1 Contrast Agents and Drug Carriers for Breast Cancer Therapy
Gadolinium-Doped Hydroxyapatite Nanorods as T1 Contrast Agents and Drug Carriers for Breast Cancer Therapy
复制标题
掺钆羟基磷灰石纳米棒作为 T1 造影剂和药物载体用于乳腺癌治疗
DOI：
10.1021/acsanm.8b02036
复制
发表时间：
2019-03-01
影响因子：
5.9
通讯作者：
Lu, Guangming
中科院分区：
文献类型：
--
作者：
Liu, Ying;Tang, Yuxia;Lu, Guangming
羟基磷灰石纳米粒子因其良好的生物相容性，在多功能纳米系统的开发中受到广泛关注。本论文通过调节钆的加入量，控制合成了掺钆羟基磷灰石纳米棒（NHA：Gd）。NHA：Gd对阿霉素具有较高的载药量（118 μg/mg）和pH响应性药物释放能力。所获得的阿霉素（DOX）负载的NHA：Gd（NHA：Gd-DOX）溶液的r1值达到0.0472（μg/mL）−1 s-1，高于市售T1造影剂Gd-DTPA的r1值（0.0314（μg/mL）−1 s-1）。体内实验表明NHA：Gd-DOX具有良好的磁共振成像性能。治疗效果的结果表明，与游离DOX相比，NHA：Gd-DOX治疗的肿瘤体积显著减小。体内毒性实验表明，NHA：Gd-DOX处理的小鼠的主要器官没有明显的损伤。考虑到良好的生物相容性，T1 WI对比度能力...
Hydroxyapatite nanoparticles have drawn much attention in the development of multifunctional nanosystems because of their excellent biocompatibility. In the report, gadolinium-doped hydroxyapatite nanorods (NHA:Gd) were controlled synthesized through adjusting the amount of gadolinium. The NHA:Gd showed a high loading capacity for doxorubicin (118 μg per milligram) and a pH-responsive drug release ability. The r1 value of obtained doxorubicin (DOX)-loaded NHA:Gd (NHA:Gd-DOX) solution reached 0.0472 (μg/mL)−1 s–1 and was higher than that of commercial T1 contrast Gd-DTPA (0.0314 (μg/mL)−1 s–1). In vivo experiments demonstrated that NHA:Gd-DOX exhibited excellent MR imaging property. The results of therapeutic efficacy demonstrate that the tumor volume treated by NHA:Gd-DOX was significantly reduced compared to that treated by free DOX. In vivo toxicity experiments demonstrated no obvious damage to the major organs in NHA:Gd-DOX treated mice. Considering the excellent biocompatibility, T1WI contrast ability...